Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(100.0%)
1Total
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02914405Phase 1Active Not Recruiting

Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma

Role: collaborator

NCT01722786Completed

Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists

Role: collaborator

NCT02956343Completed

SmartWATCHes for Detection of Atrial Fibrillation

Role: collaborator

NCT02949180Completed

Enhanced Diagnostics for Early Detection of Atrial Fibrillation - Prospective Validation

Role: collaborator

NCT02187263Unknown

German Centre for Cardiovascular Research Cardiomyopathy Register

Role: collaborator

All 5 trials loaded